Expert Interview
A look at AstraZeneca's PARP1 inhibitor, saruparib, in solid tumors and the results from the phase 1/2a PETRA study presented at the 2024 AACR Annual Meeting.
Ticker(s): AZNInstitution: Yale Cancer Center
- Professor, Co-Chief, and Clinical Research Team Leader in Gynecologic Oncology at Yale Cancer Center.
- Treats 50 patients with with BRCA1/2, PALB2 or RAD51C/D mutations.
- Research focuses on immunotherapy for ovarian, cervical and endometrial carcinomas refractory to standard treatment modalities; development of therapeutic vaccines against Human Papillomavirus (HPV) infected genital tumors, and the use of monoclonal antibodies against chemotherapy resistant gynecologic malignancies.
Roughly how many patients do you treat with solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations?
What are your thoughts on the phase 1/2a PETRA study presented at the 2024 AACR Annual Meeting?
Added By: sara_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of saruparib, what would it be and why?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
